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Abstract
Introduction: An NZB-derived genetic locus (Sle2c2) that suppresses autoantibody production in a mouse model
of induced systemic lupus erythematosus contains a polymorphism in the gene encoding the G-CSF receptor. This
study was designed to test the hypothesis that the Sle2c2 suppression is associated with an impaired G-CSF
receptor function that can be overcome by exogenous G-CSF.
Methods: Leukocytes from B6.Sle2c2 and B6 congenic mice, which carry a different allele of the G-CSF receptor,
were compared for their responses to G-CSF. Autoantibody production was induced with the chronic graft-versus-
host-disease (cGVHD) model by adoptive transfer of B6.bm12 splenocytes. Different treatment regimens varying the
amount and frequency of G-CSF (Neulasta®) or carrier control were tested on cGVHD outcomes. Autoantibody
production, immune cell activation, and reactive oxygen species (ROS) production were compared between the
two strains with the various treatments. In addition, the effect of G-CSF treatment was examined on the
production autoantibodies in the B6.Sle1.Sle2.Sle3 (B6.TC) spontaneous model of lupus.
Results: B6.Sle2c2 and B6 leukocytes responded differently to G-CSF. G-CSF binding by B6.Sle2c2 leukocytes was
reduced as compared to B6, which was associated with a reduced expansion in response to in vivo G-CSF
treatment. G-CSF in vivo treatment also failed to mobilize bone-marrow B6.Sle2c2 neutrophils as it did for B6
neutrophils. In contrast, the expression of G-CSF responsive genes indicated a higher G-CSF receptor signaling in
B6.Sle2c2 cells. G-CSF treatment restored the ability of B6.Sle2c2 mice to produce autoantibodies in a dose-
dependent manner upon cGVHD induction, which correlated with restored CD4+ T cells activation, as well as
dendritic cell and granulocyte expansion. Steady-state ROS production was higher in B6.Sle2c2 than in B6 mice.
cGVHD induction resulted in a larger increase in ROS production in B6 than in B6.Sle2c2 mice, and this difference
was eliminated with G-CSF treatment. Finally, a low dose G-CSF treatment accelerated the production of anti-
dsDNA IgG in young B6.TC mice.
Conclusion: The different in vivo and in vitro responses of B6.Sle2c2 leukocytes are consistent with the mutation in
the G-CSFR having functional consequences. The elimination of Sle2c2 suppression of autoantibody production by
exogenous G-CSF indicates that Sle2c2 corresponds to a loss of function of G-CSF receptor. This result was
corroborated by the increased anti-dsDNA IgG production in G-CSF-treated B6.TC mice, which also carry the Sle2c2
locus. Overall, these results suggest that the G-CSF pathway regulates the production of autoantibodies in murine
models of lupus.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease with a complex etiology in which the production
of pathogenic autoantibodies (autoAbs) results in cellu-
lar and tissue damage. Aside from B cells, which pro-
duce these autoAbs, and CD4+ T cells, which provide B
cell help for the generation of class-switched, affinity
maturated autoAbs, essentially every other immune cell
subset has been implicated in SLE pathogenesis. The
strong genetic basis of SLE is sustained by a large num-
ber of polymorphisms that have been identified in
recent years through association studies in large cohorts
of patients and controls [1]. Mouse models of SLE have
been used extensively to study both the cellular and
genetic basis of SLE, and overall, the results obtained
from these models have largely been validated in SLE
patients. In particular, murine models have revealed a
large number of SLE susceptibility genes, which are
organized in the same three broad pathways: apoptosis
and processing of apoptotic debris, toll-like receptor
(TLR) signaling and type I IFN pathways, and lympho-
cyte activation in both SLE patients and SLE-prone mice
[2,3]. The genetic analysis of the NZM2410 mouse
model has also shown the existence of both SLE-resis-
tance and suppressor genes. Consequently, the SLE-
resistant strain C57BL/6 (B6) carries susceptibility genes
that were revealed when combined with either other
susceptibility genes provided by the NZM2410 lupus-
prone genome, or when subjected to a strong immune
stimulation [4,5].
The bm12- chronic graft vs host disease (cGVHD)
model is a well-defined model of induced lupus in
which B6.C-H2bm12 lymphocytes are transferred into H-
2b B6 hosts. Within 3 weeks of transfer, mice develop
lupus-like phenotypes including lymphocyte activation
and anti-nuclear autoAbs, which are dependent on
interactions between donor CD4+ T cells and host auto-
reactive B cells [6]. We have shown that B6.Sle2c2 mice,
which are B6 mice carrying an NZM2410 (NZB)-derived
genomic region on the telomeric potion of the Sle2
locus, are profoundly resistant to bm12-cGVHD induc-
tion as compared to their B6 congenic controls [5].
Using mixed bone-marrow (BM) chimeras and func-
tional assays, we have shown that Sle2c2 suppression is
mediated by BM-derived cells, but not by T cells, B
cells, or dendritic cells (DCs). We mapped Sle2c2 resis-
tance to a short genomic interval that contains Csf3r,
the gene encoding for the granulocyte-colony stimula-
tion factor (G-CSF) receptor (G-CSFR) [5]. The
NZM2410 allele of Csf3r (Csf3rN as opposed to the B6
allele Csf3rB) carries a mutation in exon 10 (rs13477964)
that results in a S378N substitution in its extracellular
domain.
G-CSF is an essential factor in the recruitment and
function of neutrophils [7]. G-CSFR expression regulates
GVHD in mice [8]. Moreover, neutrophils have recently
been implicated at multiple levels in the pathology of
SLE or related systemic autoimmune diseases [9]. Neu-
trophils inflict direct damage to the vasculature [10], the
kidneys [11] and the skin [12] of lupus patients. They
also contribute to SLE pathogenesis through their direct
production of type I IFN [13], or through the highly
immunogenic neutrophil extracellular traps (NETs)
amplifying the production of either type I IFN [14] or
IL-17 [15], although these later findings have been
refuted in the MRL/lpr lupus-prone mouse model [16].
G-CSF also controls the number of myeloid derived
suppressor cells (MDSCs) [17], which are potent sup-
pressors of alloreactive T cell responses in a GVHD
model [17]. In MRL/lpr mice, the percentage of MDSCs
increases as disease progresses [18], corroborating our
findings of an expanded GR1lo MDSC population in B6
mice with established cGVHD [5].
These studies lead us to hypothesize that the N378S
mutation in the Csf3r gene impairs G-CSFR function.
This mutation is located in the solvent-exposed part of
the receptor in a putative fibronectin III domain outside
the solved structure of the protein [5]. It is therefore
impossible at this point to predict its functional signifi-
cance, although it has the potential to affect ligand bind-
ing. We hypothesized that the N378S mutation is
responsible for the differential bm12-cGVHD response
between B6 and B6.Sle2c2 mice, which we tested by
comparing their response to exogenous G-CSF. We rea-
soned that if bm12-cGVHD resistance in B6.Sle2c2 mice
was mediated by a gain of function in suppressive cells
such as MDSCs, G-CSF treatment would induce bm12-
cGVHD resistance in B6 mice. In contrast, if bm12-
cGVHD resistance in B6.Sle2c2 mice was due to a loss
of function or recruitment in inflammatory neutrophils,
then G-CSF treatment would alleviate bm12-cGVHD
resistance in B6.Sle2c2 mice, which would develop auto-
Abs and lymphocyte activation comparable to that of
B6. Here we demonstrate a weaker binding of mouse G-
CSF to B6.Sle2c2 leukocytes as compared to B6, as well
as a defective expansion of B6.Sle2c2 myeloid cells and
neutrophils in response to in-vivo G-CSF treatment.
Furthermore, exogenous G-CSF restored bm12-cGVHD
responses in B6.Sle2c2 mice. Finally, the B6.Sle1.Sle2.
Sle3 congenic mice that display a full-blown sponta-
neous lupus as its NZM2410 parental strain carry the
Sle2c2 locus [19]. It was therefore predicted that G-CSF
treatment would accelerate their autoAb production,
which we showed in this study with a low-dose treat-
ment. Overall these results suggest that Sle2c2 prevents
the induction of systemic autoimmunity by impairing
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the production of inflammatory neutrophils due to a
decreased ability of the G-CSFR to bind its ligand.
Materials and methods
Mice
The B6.Sle2c2 mice carrying an NZM2410 (NZB)-derived
interval located between D4Mit11 and D4Mit72 have
previously been described [5]. B6 and B6.C-H2bm12/KhEg
(bm12) were originally purchased from the Jackson
Laboratory (Bar Harbor, ME, USA). Cohorts of mice
within an experiment were sex- and age-matched, but the
reported phenotypes were neither affected by sex or age.
The NZM2410-derived triple congenic mice B6.Sle1.Sle2.
Sle3 (B6.TC) have been previously described [19]. All ani-
mal protocols were approved by the Institutional Animal
Care and Use Committee at the University of Florida.
cGVHD induction and G-CSF treatment
bm12-cGVHD was induced according to an established
protocol [6]. Briefly, 50 to 80 × 106 bm12 splenocytes
were injected intraperitoneally into 2 to 4 month-old B6
or B6.Sle2c2 mice. Serum was collected for autoAb detec-
tion by ELISA as previously described [6] at day (d) 0, 7,
14 and 21 after induction. Antinuclear antibody (ANA)
stains were conducted on slides containing fixed Hep-2
cells (Inova Diagnotics, San Diego, CA, USA) with mouse
sera diluted 1:40, and revealed with fluorescein isothiocya-
nate (FITC)-conjugated anti-mouse IgG (Southern Bio-
tech, Birmingham, AL, USA) at 1:50 dilution. Staining
intensity was calculated with morphometry software
(Metamorph, Molecular Devices, Sunnyvale, CA, USA) for
a standardized level of green fluorescence averaged on 10
to 20 randomly selected Hep-2 cells per sample. Samples
with an average staining intensity > 1 were considered
positive. At d21, mice were sacrificed and splenocytes
assessed by flow cytometry.
bm12-cGVHD-induced mice were treated with subcuta-
neous injections of 1.2, 12.0, or 120.0 ug pegylated human
G-CSF (Neulasta®, huG-CSF, Amgen, Thousand Oaks,
CA, USA), all starting at d1 of induction. Some huG-CSF
injections were repeated every 7 d resulting in 4 different
treatment regimens: one injection of 120 ug (120 × 1), two
or three injections of 12 ug (12 × 2 and 12 × 3), and three
injections of 1.2 ug (1.2 × 3). Control mice were injected
with 5% dextrose as vehicle control. Each experimental
group contained at least five recipient mice per treatment
per strain, and control groups were performed side by side
for each treatment group. Groups of four un-manipulated
mice per strain were injected with huG-CSF and blood
was collected every 2 to 3 d to compare the dose-response
effect of G-CSF of peripheral blood leukocytes (PBLs)
between strains. Serum mouse (m) G-CSF was measured
by ELISA with reagents from Peprotech (Rocky Hills, NJ,
USA) in sera diluted 1:50. B6.TC and B6 female mice were
treated with six weekly injections of 1 ug of Neulasta or
5% dextrose starting at 2 months of age and were sacri-
ficed at week 7. Serum was collected every two weeks and
anti-dsDNA IgG, anti-chromatin IgG and total IgG were
measured as previously described in sera diluted at 1:100
and 1:5000, respectively [6].
Flow cytometry
Splenocytes or PBLs were blocked with anti-CD16/CD32
(2.4G2), then stained with pre-titrated amounts of the fol-
lowing FITC-, phycoerythrin (PE)-, allophycocyanin-, or
biotin-conjugated Abs: CD4 (RM4-5), CD69 (H1.2F3),
CD44 (IM7), CD62L (MEL-14) B220 (RA3-6B2), CD86
(GL1), CD80 (16-10A1), CD22.2 (Cy34.1), I-ab (AF6-
120.1), CD11b (M1/70), CD11c (HL3), Ly6C/G (GR-1/
RB6-8C5) or isotype controls, all from BD Biosciences (San
Diego, CA, USA). Biotinylated Abs were revealed by strep-
tavidin-PercP-Cy5a. p-signal transducer and activator of
transcription 3 (Stat3) (Y705) staining was performed after
fixation and permeabilization (BD Cytofix/Cytoperm kit).
G-CSF binding was performed by incubating splenocytes
for 1 h with 25 ng of mG-CSF (ProSpec, East Brunswick,
NJ, USA) biotinylated with a Biotin XX Microscale protein
labeling kit (Molecular Probes, Eugene, OR, USA), detected
by flow cytometry with PE-streptavidin. As negative con-
trols, cells were incubated only with PE-streptavidin. ROS
production was detected with 1 μM dihydrorhodamine 123
(DHR, Molecular Probes). Cell staining was analyzed using
a FACScalibur or LSRFortessa (Becton Dickinson, Franklin
Lakes, NJ, USA). At least 30,000 (PBLs) and 50,000 (sple-
nocytes) events were acquired per sample, and dead cells
were excluded based on scatter characteristics.
Gene expression analysis
Splenocytes and BM cells from B6 and B6.Sle2c2 mice
(three each) were cultured in complete medium at a con-
centration of 106 cells/ml with 0.0, 0.1, or 1.0 ug/ml of
Neulasta for 8 h. RNA was extracted and cDNA was
synthesized as previously described [20]. Expression of
Itgam and Mpo relative to Gapdh was quantified by quan-
titative PCR measuring the incorporation of Sybergreen
(Molecular Probes). The primer sequences were: Itgam 5’-
CCC CAA TTA CGT AGC GAA TG-3’and 5’- TGC TGC
GAA GAT CCT AGT TG -3’; Mpo 5’- TGC TCT CGA
ACA AAG AGG GT-3’ and 5’- CTT TGA CAG CCT
GCA CGA-3’; Gapdh 5’- AGC TTG TCA TCA ACG
GGA AG -3’ and 5’- GTG GTT CAC ACC CAT CAC AA
-3’. Results were calculated with the ΔΔ cycle threshold
(Ct) method and normalized to the average values for
untreated B6 samples.
Statistics
Statistical analyses were performed with GraphPad
Prism5, using the two-tailed unpaired t-test or Bonfer-
roni multiple comparison test when multiple groups
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were compared. Non-parametric statistics were per-
formed when data were not normally distributed.
Graphs show mean and standard error of the mean
(SEM), and statistical significance is represented as *P <
0.05, **P < 0.01, and ***P < 0.001.
Results
B6.Sle2c2 leukocytes bind less G-CSF and expand less to
exogenous G-CSF than B6
To determine whether the S378N mutation in the extra-
cellular domain of the G-CSFR-affected ligand binding,
we compared in vitro binding of mG-CSF between B6
and B6.Sle2c2 splenocytes. As expected, the highest bind-
ing was found on GR1hi CD11b+ neutrophils, whereas
intermediate levels were found on GR1lo CD11b+ and B
cells (Figure 1A). However, every B6.Sle2c2 cell subset
showed a significantly lower binding of mG-CSF, either
as percentage of G-CSF+ cells (Figure 1A), or as the
mean fluorescence intensity (data not shown). This was
not due to different endogenous levels of G-CSF, since
the two strains presented similar serum G-CSF levels
(B6, 1.10 ± 0.21 ng/ml; B6.Sle2c2, 1.44 ± 0.39 ng/ml, n =
20 per strain). To test whether the decreased G-CSF
binding by B6.Sle2c2 leukocytes provides functional con-
sequences, we compared the effect of in vivo huG-CSF
treatment on the expansion of myeloid cells between the
two strains (Figure 1B). Although human and mouse G-
CSF are not identical, a large number of studies, includ-
ing one by our group [21], have shown that huG-CSF is
fully functional in mice. The pegylated form of G-CSF in
Neulasta has an extended half-life and a time course ana-
lysis showed that the maximum response occurs 4 d after
treatment (data not shown). At that time point, a dose-
dependent expansion of CD11b+, GR1hi CD11b+ and
GR1lo CD11b+ PBLs was observed in both strains but a
greater amount of hu-G-CSF was required for B6.Sle2c2
cells to achieve the level of B6 cell expansion (Figure 1B).
One of the functions of G-CSF is to mobilize neutrophils
from BM to the periphery [7]. We therefore compared the
numbers of neutrophils in the BM and the spleen of B6
and B6.Sle2c2 mice 4 d after treatment with G-CSF or
dextrose control (Figure 2). As expected, the percentage of
neutrophils decreased in the BM of G-CSF-treated B6
mice (Figure 2A and 2C) and increased in their spleens
(Figure 2B and 2C). In contrast, the percentage of neutro-
phils in the BM of G-CSF-treated B6.Sle2c2 mice was
higher than in the BM of dextrose-treated mice (Figure 2A
and 2C), which corresponded to a lack of mobilization of
the B6.Sle2c2 neutrophils to the spleen (Figure 2B and
2C). The percentages of neutrophils in the blood of these
G-GCF-treated mice reflected this difference in mobiliza-
tion, with an increased percentage of circulating B6 neu-
trophils but a decreased percentage of circulating B6.
Sle2c2 neutrophils (Figure 2D).
To determine whether G-CSF signaling differed
between B6.Sle2c2 and B6 leukocytes, we used three
well-known targets, CD11b and myeloperoxidase (MPO)
expression and STAT3 phosphorylation [22]. Ex vivo,
CD11b expression on splenocytes was higher in B6.
Sle2c2 than in B6 mice (Figure 3A). Treatment with 120
ug of hu-G-CSF significantly increased CD11b expres-
sion on CD11b+ PBLs in both strains, but it remained at
a higher level on B6.Sle2c2 cells. This effect of exogen-
ous G-CSF was abolished by d9 after injection. Similar
results were obtained with the expression of CD16/32
(another G-CSF-responsive gene) on CD11b+ PBLs (data
not shown). We next compared CD11b/Itgam and Mpo
message expression in BM and spleen cells obtained
from B6 and B6.Sle2c2 mice 4 d after treatment with 1
ug hu-G-CSF, then treated for 8 h with hu-G-CSF in
vitro (Figure 3B). In both strains, we observed that hu-
G-CSF decreased both Itgam and Mpo expression. The
response pattern was however different between the two
strains, with B6.Sle2c2 cells being more responsive than
B6 at equal doses. In addition, we observed, as for
CD11b protein expression after the in vivo treatment
(Figure 3A), an overall higher expression of Itgam and
Mpo in B6.Sle2c2 than in B6 cells. Ex vivo STAT3 phos-
phorylation was also significantly higher in splenocytes
from untreated B6.Sle2c2 mice; either when considering
the percentage of CD11b+, GR1hi CD11b+ and GR1lo
CD11b+ cells expressing pSTAT3 (Figure 3C), or
pSTAT3 mean fluorescence intensity (data not shown).
Although factors other than G-CSF signaling may con-
tribute to the differential CD11b expression and STAT3
phosphorylation, the two strains only differ by the
Sle2c2 interval (< 15 Mb) [5]. While these results
demonstrate a lower G-CSF binding and expansion to
exogenous G-CSF by leukocytes expressing the Sle2c2
Cfs3r allele, evidence of greater G-CSFR signaling in leu-
kocytes expressing the Sle2c2 Cfs3r allele was also
observed. These apparently paradoxical results should
be put in perspective that very little is known about
G-CSFR signaling and G-CSFR-responsive genes in pri-
mary myeloid cells, as all the studies have been per-
formed with myeloid cell lines (reviewed in [22]). Our
results however clearly showed that B6 and B6.Sle2c2
myeloid cells respond differently to G-GSF both in vivo
and in vitro by multiple processes, including myeloid/
granulocyte expansion, mobilization, and G-CSFR-
responsive gene expression.
Exogenous G-CSF restores cGVHD responses in
B6.Sle2c2 mice
If the S378N mutation in the G-CSFR is responsible
for the cGVHD resistance in B6.Sle2c2 mice, we postu-
lated that huG-CSF treatment should eliminate the dif-
ference in cGVHD response between B6 and B6.Sle2c2
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mice. If resistance in B6.Sle2c2 mice is due to a G-
CSFR loss of function, huG-CSF treatment should
restore cGVHD response in B6.Sle2c2 mice. On the
other hand, if resistance is due to a G-CSFR gain of
function, cGVHD resistance would be expected in
huG-CSF-treated B6 mice. Based on our time course
analysis showing a maximal effect at d4 after injection
that was eliminated at d7, we tested a combination of
treatment protocols in which the dose (1.2, 12.0, or
120.0 ug) and the frequency (one-, two-, or three-
weekly injections starting at cGVHD induction) varied.
Two treatment protocols (120 × 1 and 12 × 2) raised
the production of anti-dsDNA IgG in B6.Sle2c2 mice
significantly above the dextrose-treated controls
(Figure 4A left), and to a level similar to the B6 con-
trols, especially in the 12 × 2 cohort. For the 120 × 1
cohort, a drop in the third week was observed, possibly
because the pharmacological effect of the single huG-CSF
Figure 1 Differential response of B6.Sle2c2 and B6 leukocytes to granulocyte-colony stimulation factor (G-CSF). (A) Mouse (m)G-CSF
binding by B6 and B6.Sle2c2 leukocytes measured with biotinylated G-CSF and steptavidin-PE (G-CSF-biot-PE). The top row shows representative
overlays of the B6 (black) and Sle2c2 (gray) histograms, with the gray-filled histograms showing the controls without added mG-CSF for the
indicated gated cell populations. (B) Total CD11b+, GR1hi CD11b+ and GR1lo CD11b+ peripheral blood leukocytes (PBLs) in untreated B6 and B6.
Sle2c2 mice (n = 6 per strain), and 4 d after injections of 1.2, 12.0 or 120.0 ug human (hu)G-CSF (n = 2 per dose per strain). The graphs show
mean and standard error of the mean with the significance value from the t-test (*P < 0.05; **P < 0.01; ***P < 0.001).
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treatment was diminishing. With these two treatment regi-
mens combined, the amount of anti-dsDNA and anti-
chromatin IgG at d21 was significantly higher in the
B6.Sle2c2 mice treated with huG-SCF than in controls
(Figure 4B). Moreover, the autoAbs produced by treated
B6.Sle2c2 mice reached equivalent levels as in treated B6
mice. cGVHD induced autoAbs in B6 mice with strong
Hep-2 staining that combined cytoplasmic and nuclear
patterns (Figure 4C). The 12 × 2 treatment induced Hep-
2-staining in B6.Sle2c2 mice similar in intensity and pat-
tern as in B6 mice (Figure 4C). Similar results were
obtained with the 120 × 1 treatment, although with a
more variable intensity (data not shown). The 1.2 × 3
treatment had no effect, indicating that the dose was too
low. The 12 × 3 treatment had an intermediate effect in
B6.Sle2c2 mice, and interestingly was the only regimen
that induced a significant decrease in the B6 anti-dsDNA
IgG response (Figure 4A right). The other treatments
showed a trend in lowering autoAbs produced by B6 mice,
but the difference was not significant. Overall, these results
demonstrate that exogenous G-CSF eliminates the resis-
tance to cGVHD induction in B6.Sle2c2 mice in a dose-
dependent manner, with no significant effect in B6 mice at
the same dose. This suggests that an impaired G-CSFR
response mediates the cGVHD resistance in the B6.Sle2c2
strain, which can be compensated by an excess G-CSF to
drive equilibrium binding or signaling to the receptor.
The restoration of cGVHD response by G-CSF increases CD4
+ T cell activation and expands the DC and neutrophil
populations
cGVHD increases the percentage of blasts and the
expression of activation markers such as class II MHC,
CD22 and CD69 on B6 but not on B6.Sle2c2 B cells [5].
Treatment with huG-CSF has minimal effects on these
B cell parameters (data not shown). It decreased CD22
expression in a dose-dependent fashion on B6 but not in
B6.Sle2c2 B cells. However, these changes in B cell activa-
tion did not correspond to the observed changes in
autoAb production. This suggested that huG-CSF did
not restore the cGVHD response through B cells. Host
CD4+ T cells are also activated by cGVHD in B6 but not
in B6.Sle2c2 mice [5]. B6.Sle2c2 mice have a significantly
greater percentage of splenic CD4+ T cells 3 weeks after
cGVHD induction (21.58 ± 0.66% vs 16.35 ± 0.48%, P <
0.001). All huG-CSF treatments reduced the size of the
CD4+ T cell compartment in both strains, and the 12 × 2
treatment, which was the most successful in restoring a
cGVHD response in B6.Sle2c2 mice, resulted in an
equivalent percentage of CD4+ T cells between strains
(17.19 ± 0.55% vs 16.18 ± 0.11%, P > 0.05). The 12 × 2
Figure 2 Differential neutrophil mobilization in response to human granulocyte-colony stimulation factor (huG-CSF) in B6 and B6.
Sle2c2 mice. Percentage of Ly6G+ CD11b+ neutrophils present in the bone marrow (BM) (A) and spleen (B) in B6 and B6.Sle2c2 mice 4 d after
an injection with 5% dextrose (Dex) or 1 ug hu-G-CSF (GCSF). The graphs show mean and standard error of the mean with the significance of
the Bonferroni multiple comparison test performed on three mice per group. The experiment was repeated and the same results were obtained,
although with different absolute values (*P < 0.05; **P < 0.01; ***P < 0.001).
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treatment also significantly increased the percentage of
CD4+ T cell blasts in B6.Sle2c2 mice (controls: B6.Sle2c2:
8.54 ± 0.54% vs B6: 16.57 ± 0.75%, P > 0.0001; 12 × 2:
14.50 ± 1.26% vs 15.64 ± 1.89%, P > 0.05), increased
CD69 expression, and reduced the naïve and expanded
the effector memory CD4+ T cells in B6.Sle2c2 mice
(Figure 5A). The similar values in 12 × 2 treated B6 and
B6.Sle2c2 mice correlated with restored autoAb produc-
tion in the B6.Sle2c2 mice (Figure 4). The percentage of
naïve CD4+ T cells was still higher in treated B6.Sle2c2
Figure 3 Differential response of the granulocyte-colony stimulation factor receptor (G-CSFR) target genes in response to G-CSF in B6.
Sle2c2 and B6 leukocytes. (A) CD11b is upregulated in B6.Sle2c2 peripheral blood leukocytes (PBLs) compared to B6 (left panel). Human (hu)G-
CSF (120 ug) injected on day (d)1 (arrow) induced a greater CD11b upregulation in B6.Sle2c2 than in B6 PBLs (middle panel, n = 4 per strain).
The overlay histograms on the right show representative CD11b expression in B6 splenocytes at d0 (dash) and d2 (black), and in B6.Sle2c2
splenocytes at d0 (filled gray) and d2 (open gray). (B) Itgam and Mpo relative gene expression in bone marrow (BM) and spleen cells cultured
for 8 h in medium alone and with 0.1 or 1.0 ug/ml hu-G-CSF. Filled bars represent B6 and open bars represent B6.Sle2c2 (n = 3 per group). In
each graph, the data were normalized to the average of untreated B6 values. (C) Intracellular pSTAT3 staining in total CD11b+, GR1hi CD11b+
and GR1lo CD11b+ splenocytes (four mice per strain). The top row shows representative overlays of the B6 (open black) and Sle2c2 (open gray)
histograms, with the filled silver histograms showing the isotype control. The graphs show mean and standard error of the mean with the
significance value from the t-test (A and C) or the Bonferroni multiple comparison test (B) (*P < 0.05; **P < 0.01; ***P < 0.001).
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than in treated B6 spleens, yet the difference was smaller
than in untreated mice (1.43- vs 2.15-fold). The huG-CSF
treatments (12 × 3 and 1.2 × 3) that did not restore auto-
Abs production in B6.Sle2c2 mice had no effect on CD4+
T cell activation (data not shown).
The percentage of CD11b+ CD11c- GR1- macrophages
was equivalent between B6 and Sle2c2 mice 3 weeks after
cGVHD induction. huG-CSF treatments increased the
percentage of macrophages in a dose-dependent manner
similarly between these two strains without any correlation
with autoAb production (data not shown). In contrast, the
percentage of CD11b+ CD11c+ myeloid dendritic cells
(DCs) was significantly lower in B6.Sle2c2 than in B6 mice,
and the 12 × 2 treatment significantly expanded this cell
population in the spleen of B6.Sle2c2 mice to a level similar
to that of treated B6 mice (Figure 5B). The percentage of
Figure 4 Exogenous human granulocyte-colony stimulation factor (huG-CSF) restores autoantibody (autoAb) production in B6.Sle2c2
mice after induction of chronic graft vs host disease (cGVHD). (A) huG-CSF-treatment induced anti-dsDNA IgG in B6.Sle2c2 mice in a dose-
dependent manner (left), but had little effect in B6 mice (right). Five mice per strain per treatment were used. (B) Anti-dsDNA and anti-
chromatin IgG found at d21 in the combined 120 × 1 and 12 × 2 cohorts. (C) Representative ANA IgG staining of Hep-2 cells incubated with
sera collected at 21 d in each of the four treatment groups in the 120 × 1 and 12 × 2 cohorts and average staining intensity of 10 to 20
randomly selected cells per sample. Means and standard error of the mean with the significance value from the t-test for comparison of treated
mice and controls (dex) are shown for each strain for a given time point in A, and from Dunnett’s multiple comparison test between groups as
indicated in B and C (*P < 0.05; **P < 0.01; ***P < 0.001).
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CD11b+ GR1hi neutrophils was significantly higher in un-
manipulated B6.Sle2c2 than in B6 mice (3.97 ± 0.55% vs
2.50 ± 0.16%, P = 0.03). Three weeks after cGVHD induc-
tion, this difference was inverted, with B6.Sle2c2 values
being significantly lower than B6 (Figure 5B). As in the
blood of non-induced mice (Figure 1B), 12 × 2 treatment
expanded the neutrophil population in the spleen and
resulted in equivalent percentages in both strains. Finally,
the percentage of CD11b+ GR1lo cells was similar
in untreated and unmanipulated B6.Sle2c2 and B6 mice
(0.49 ± 0.04 vs 0.50 ± 0.02%, P > 0.05), but three weeks
after cGVHD induction, this population was significantly
depleted in B6.Sle2c2 mice (Figure 5B). Also as in the
blood of non-induced mice (Figure 1B), the 12 × 2
expanded the CD11b+ GR1lo population in B6.Sle2c2 mice
three weeks after cGVHD induction and resulted in
equivalent percentages in both strains (Figure 5B). Overall,
these results showed that restoration of the cGVHD
response in B6.Sle2c2 mice by huG-CSF treatment corre-
lated with an increase in CD4+ T cell activation, and an
expansion of the DC, neutrophils and CD11b+ GR1lo cell
populations.
Reactive oxygen species (ROS) production is differentially
up-regulated in the cGVHD response between B6.Sle2c2
and B6 mice
B6.Sle2c2 spleens contain significantly more ROS+ granu-
locytes cells (Figure 6A and 7B) and myeloid (Figure 6B
and 7A) than B6, although no difference was observed
for the intensity of ROS expression (mean fluorescence
intensity, MFI) on ROS+ cells (data not shown). The
same result was obtained with PBL (data not shown).
Bm12-cGVHD induction expanded by over 5-fold the
population of ROS+ granulocytes in both strains, and
eliminated the difference between strains (Figure 6A and
7D). The percentage of ROS+ myeloid splenocytes
was also similar between strains after cGVHD induction
(Figure 6B and 7C). The ROS MFI was, however, signifi-
cantly higher on B6 than B6.Sle2c2 granulocytes after
cGVHD induction (Figure 6C). A time course analysis of
ROS expression in B6 and B6.Sle2c2 PBLs at d3, 10 and 21
after cGVDH induction demonstrated a robust ROS induc-
tion in both strains, but that reached significantly higher
levels in B6 than in B6.Sle2c2 mice at d21 (Figure 6D). The
12 × 2 treatment induced a higher ROS production in B6.
Figure 5 Restoration of chronic graft vs host disease (Cgvhd)-induced autoantibody (autoAb) by human granulocyte-colony
stimulation factor (huG-CSF) correlates with CD4+ T cell activation, as well as DC and GR-1+ cell expansion. (A) huG-CSF 12 × 2
treatment increased CD69 expression, reduced the percentage of naïve CD62L+ CD44- CD4+ T cells and expanded the percentage of the CD62L-
CD44+ effector memory CD4+ T cells in B6.Sle2c2 mice compared to dextrose-treated controls. (B) huG-CSF 12 × 2 treatment increased the
percentage of CD11b+ CD11c+, GR1hi CD11b+ and GR1lo CD11b+ cells in B6.Sle2c2 mice compared to dextrose-treated controls. Means and
standard error of the mean are shown with the significance value from Dunnett’s multiple comparison tests between groups with five mice per
group (*P < 0.05; **P < 0.01; ***P < 0.001).
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Sle2c2 PBLs eliminating the difference with B6 mice, either
treated or controls (Figure 6D). Therefore, steady state
levels of ROS are higher in B6.Sle2c2 than in B6 mice.
cGVHD induction greatly upregulates ROS production to
a higher level in B6 than in B6.Sle2c2 mice, which is cor-
rected by huG-CSF treatment. Taken together, these
results suggest that variations in ROS production regulate
the cGVHD response and that G-CSF signaling contributes
to these variations.
Exogenous G-CSF accelerates anti-dsDNA IgG in lupus-
prone B6.TC mice
B6.TC mice first produce anti-chromatin IgG between 2
to 3 months of age then anti-dsDNA IgG between 4
and 5 months of age [19]. The presence of Sle2c2 in the
B6.TC genome predicts that G-CSF treatment would
accelerate their autoAb production as it did in the
induced lupus model. We treated 2-month-old B6.TC
and B6 female mice with six weekly injections of either
1ug hu-G-CSF or dextrose. It has been shown that neu-
tralizing anti-hu G-CSF antibodies develop with a
greater number of injections [23]. G-CSF treated B6.TC
mice developed anti-dsDNA IgG significantly faster than
control mice (Figure 8A). The G-CSF treatment did not
induce anti-dsDNA IgG in B6 mice (Figure 8B). G-CSF,
however, had no effect on anti-chromatin IgG, which
increased at a similar rate in both treated and control
B6.TC mice, and stayed at background levels in treated
and control B6 mice (Figure 8C). G-CSF treatment did
not affect total IgG levels (Figure 8D) or IgM (data not
shown) in either strain, indicating that the effect of G-
GSF was specific for anti-dsDNA IgG. This was con-
firmed when the production of anti-dsDNA IgG was
normalized to total IgG (Figure 8E). It was not the case
for anti-chromatin IgG (Figure 8F), which may be
related to the fact that the anti-chromatin response was
Figure 6 Reactive oxygen species (ROS) production is differentially upregulated between B6.Sle2c2 and B6 mice. B6.Sle2c2 mice present
a higher percentage of GR1+ (A) and CD11b+ (B) splenocytes than B6. Bm12-chronic graft vs host disease (cGVHD) expands the GR1+ ROS+ in
both strains, but eliminates the differences between strains. (C) At day (d)21 after cGVHD induction the ROS mean fluorescence intensity (MFI)
was significantly higher in B6 GR1+ splenocytes than in B6.Sle2c2. (D) Time course analysis of ROS MFI in total peripheral blood leukocytes (PBLs)
during cGVDH induction in mice treated with 12 × 2 human granulocyte-colony stimulation factor (huG-CSF). Means and standard error of the
mean for five mice per group, with the significance value from the t-test are shown (*P < 0.05; ** P < 0.01). These data are representative of two
sets of experiments.
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already ongoing when the treatment was initiated.
Nevertheless, these results show that exogenous G-CSF
increased production of anti-dsDNA IgG in mice carry-
ing the Sle2c2 locus in a spontaneous model of lupus.
Discussion
This study was performed to test the hypothesis that the
S378N mutation in the Csf3r gene results in defective G-
CSFR signaling and is responsible for the differential
autoimmune response between B6 and B6.Sle2c2 mice.
In our previous study, we speculated that bm12-cGVHD
resistance in B6.Sle2c2 mice was mediated by enhanced
MDSC function or number. However, G-CSF treatment
did not induce bm12-cGVHD resistance in B6 mice, but
instead eliminated bm12-cGVHD resistance in B6.Sle2c2
mice. We therefore conclude that B6.Sle2c2 mice are
resistant to autoimmunity due to their incapacity to
mobilize pro-inflammatory G-CSF-responsive BM-
derived cells, most likely neutrophils. Indeed, we report
here that B6.Sle2c2 leukocytes bind less G-CSF and
expand less in response to in vivo G-CSF treatment. On
the other hand, G-CSFR-responsive genes are expressed
at higher levels in B6.Sle2c2 leukocytes, which present a
greater STAT3 phosphorylation, indicating a higher
level of G-CSFR signaling. Although the lower cell
expansion to G-CSF and the higher G-CSFR signaling
suggest opposing responses, it is possible that the latter
is a steady-state compensatory response to the former.
This hypothesis will require extensive comparison of G-
CSFR signaling between the two alleles, including in cell
lines transfected with G-CSFR constructs differing only
at S378N.
The lower binding of G-CSF and impaired cellular
expansion in response to exogenous G-CSF lead us to
hypothesize that exogenous G-CSF would compensate
for a loss of function phenotype. To this end, we indeed
found that two huG-CSF treatment regimens restored
the production of autoAbs to a level similar to that
found in B6. These treatments also restored CD4+ T
cell activation as well as DC and granulocyte expansion
in B6.Sle2c2 mice to the same levels as in B6. This sug-
gested that these cell populations are effectively modi-
fied by higher G-CSF availability and they are involved
in the production of autoAbs in this model.
We also found that B6.Sle2c2 myeloid cells and granu-
locytes produced more ROS at steady-state than B6 cells.
A recent study found a strong association between a cod-
ing mutation in the human NCF2 gene with SLE suscept-
ibility, and determined that the disease associated allele
was associated with a lower ROS production [24]. This is
consistent with decreased levels of Ncf1, a gene encoding
for another unit of the nicotinamide adenine dinucleotide
phosphate-oxidase (NADPH) oxidase complex, being
associated with collagen-induced arthritis [25] and
experimental allergic encephalomyelitis [26]. Upon
bm12-cGVHD induction, ROS production is upregulated
to a greater level in the B6 than B6.Sle2c2 granulocytes.
huG-CSF treatment increased ROS production in B6.
Figure 7 Representative fluorescence-activated cell sorting (FACS) plots of reactive oxygen species (ROS) production in B6 and B6.
Sle2c2 splenocytes. Splenocytes were co-stained for CD11b (A and C) or GR1 (B and D) in un-induced mice (d0) and at d21 after bm12-chronic
graft vs host disease (cGVHD) induction. The positions of the quadrants were determined with anti-CD11 and anti-GR1 isotype controls, and with
cells stained with surface makers in the absence of the Dihydrorhodamine 123 (DHR) dye. The percentages correspond to double-positive ROS+
CD11b+ or GR1+ live splenocytes.
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Sle2c2 mice, which was concomitant with their produc-
tion of autoAbs. These results suggest that the NZM2410
allele of Csf3r results in a higher ROS production at
steady state levels of G-CSF that maintains CD4+ T cell
tolerance, as it has been shown in other models [27]. We
showed here that bm12-cGVHD induction recruits
inflammatory neutrophils, as is the case in human SLE
[28], of which B6.Sle2c2 mice cannot achieve the same
expansion as B6 mice unless exogenous G-CSF is pro-
vided. Signaling through the G-CSFR is critical for the
development and function of inflammatory granulocytes,
whereas G-CSFR deficiency is protective in collagen-
induced arthritis [29]. We therefore propose that
impaired G-CSF binding and G-CSFR signaling is protec-
tive again systemic autoimmunity in two phases, first by
producing higher levels of ROS, which maintains T cell
Figure 8 Human granulocyte-colony stimulation factor (huG-CSF) treatment accelerates anti-dsDNA IgG production in B6.TC mice.
Anti-dsDNA IgG production in B6.TC mice (A) and B6 controls (B) that were treated weekly with 1 ug huG-CSF (GCSF) or 5% dextrose (dextrose)
starting at 2 months of age (n = 3 per group). Results for B6.TC mice were normalized to their individual anti-dsDNA IgG levels before treatment
(week 0) set as 1. Results for B6 were normalized to the average units of all B6.TC mice before treatment to account for the large difference
between B6.TC and B6 anti-dsDNA IgG production. (C) Anti-chromatin IgG production in the four cohorts. Unit values are shown because
minimal variation was observed before treatment between and within cohorts. The regression lines between the huG-CSF-treated B6.TC and B6
cohorts have significantly different slopes (P = 0.005) but not between dextrose-treated cohorts (P = 0.17). (D) Total serum IgG in the four
cohorts. B6.TC mice had significantly more IgG than B6 before treatment (152 vs 95 ug/ml, P = 0.001), but that difference disappeared with time.
The huG-CSF treatment did not change total IgG production in neither strain. Anti-dsDNA (E) and chromatin (F) IgG in B6.TC mice normalized to
their total IgG production. The autoantibody (autoAb) unit/total IgG ratios were normalized to the individual values before treatment set as 1.
The graphs show mean and standard error of the mean at the indicated time points after treatment. For A and E, the P-values correspond to an
F-test comparing the slopes for the two linear regression lines corresponding to the two treatments.
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tolerance, and second by failing to support the expansion
of inflammatory neutrophils, which can amplify the auto-
immune response either through the type I IFN or Th17
pathways [9].
We have previously reported that there is no differ-
ence in Csf3r expression between B6 and B6.Sle2c2 mice
[5]. Genomic sequencing of the Csf3r locus has identi-
fied a large number of intronic polymorphisms and four
coding synonymous mutations, but S378N was the only
coding non-synonymous mutation identified between
the NZM2410 and B6 genomes (unpublished observa-
tions). None of the genes located within Sle2c2 locus
have known functions in the G-CSF pathway. This
implies that the differences that we report here between
B6 and B6.Sle2c2 mice in their response to G-CSF are
most likely due to the S378N polymorphism. This will,
however, need to be formally addressed by stringent
structure/function studies.
We have used the bm12-cGVHD model to test the
hypothesis that Sle2c2 suppression involves the G-CSF
pathway, as it is a very robust model that leads to a
rapid synchronized production of autoAbs with very lit-
tle inter-individual variation. However, we have evidence
that Sle2c2 also suppresses spontaneous autoimmune
responses in two NZM2410-derived models [30,31] and
we have now shown that a low-dose treatment with G-
CSF accelerates the spontaneous production of anti-
dsDNA IgG in B6.TC mice, which includes Sle2c2 [19].
An association between G-CSF treatment and disease
exacerbation is supported by clinical findings, where G-
CSF treatment of neutropenic SLE patients can be asso-
ciated with severe flares [32]. Moreover, depending on
the dose, G-CSF treatment can either prevent or acceler-
ate disease in the MRL/lpr mouse model of SLE [33].
While these two reports did not explore the mechanism
of disease exacerbation, we propose that it overlaps with
the resistance or susceptibility to induced autoAb pro-
duction mediated by the S378N G-CSFR polymorphism,
and that the B6.Sle2c2 and B6.TC strains offer an excel-
lent model to identify the cellular and molecular bases on
how G-CSF modulates SLE pathogenesis.
Contrary to the results reported here, G-CSF treat-
ment has been reported to promote reversal [21] or pre-
vention [34] of type 1 diabetes in the NOD mouse. In
this model, NADPH oxidase impairment through Ncf1-
deficiency was associated with disease protection [35],
contrary to the results obtained in SLE patients with
NCF2-impaired function [24]. These results suggest an
inverse correlation between the protective effect of exo-
genous G-CSF and the protective effect of the NADPH
oxidase products in autoimmune diseases. This has sig-
nificant implications for devising strategies targeting the
G-CSF pathways in opposite direction in diseases such
as SLE and type I diabetes.
Conclusions
Exogenous G-CSF increases the production of autoAb in
B6.Sle2c2 and B6.TC mice and both of these strains carry
the same mutation in the G-CSFR. Furthermore, we have
shown a defective mobilization of BM neutrophils in
response to G-CSF treatment of B6.Sle2c2 mice as well as
a different expression of G-CSF-responsive genes between
B6 and B6.Sle2c2 mice. Overall, these data suggest that
mice carrying the G-CSFR mutation are defective in mobi-
lizing and/or activating inflammatory neutrophils, which
inhibits the production of autoAbs. Further experiments
will be required to demonstrate a direct role of neutrophils
in this process.
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